DBV Technologies | DBVT - Net Income


DBV Technologies reported $-33.16M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025